ResMed Inc.

Greetings, and welcome to the Q3 fiscal year 2025 ResMed earnings conference call. My name is Kevin, and I'll be your operator for today's call. At this time, all participants are in listening-only mode, and also please note this conference call is being recorded. Later, we'll conduct a question-and-answer session. Let me hand the call over to ResMed's chairman and CEO, Mick Farrell, for a brief introduction of Sally Schwartz, who recently joined the company as Chief Investor Relations Officer. Mick, please go ahead.

Thank you, Kevin. I'm very excited to have Sally join the ResMed team, our newest ResMedian. She joined us earlier this week and brings more than two decades of experience across capital markets, healthcare, and technology. We look forward to Sally helping us to take investor relations to the next level here at ResMed, providing clarity, transparency, and long-term alignment amongst current and future investors and all of our stakeholders. So Sally, we're thrilled to have you on board.

Thanks, Nick. I'm happy to be here and I look forward to meeting our investors very soon. But first, I want to welcome our listeners to ResMed's third quarter fiscal year 2025 earnings call. We are live webcasting this call and the replay will be available on the investor relations section of our corporate website later today. Our earnings press release and presentation are both available online now. During today's call, we will discuss several non-GAAP measures that we believe provide useful information for investors. This information is not intended to be considered in isolation or as a substitute for GAAP financial information. We encourage you to review the supporting schedules in today's earnings press release to reconcile these non-GAAP measures with the GAAP reported numbers. In addition, Our discussion today will include forward-looking statements, including, but not limited to, expectations about our future financial and operating performance. We make these statements based on reasonable assumptions. However, our actual results could differ. Please review our SEC filings for a complete discussion of the risk factors that could cause our actual results to differ materially from any forward-looking statements made today. I'll now turn the call over to Mick.